Pharmadrug Inc (CSE:PHRX, OTCQB:LMLLF) CEO Daniel Cohen tells Proactive it has provided an update on multiple activities currently underway which support its 'pipeline-in-a-pill' approach in the development of PD-001 - its patented, orally bioavailable version of cepharanthine for the treatment of cancer and infectious disease. The company said that following the submission of its Type B pre-IND (investigational new drug application) meeting request and briefing package to the Food and Drug Administration, it received a written response regarding its clinical development plan for PD-001 as a potential oral antiviral pill for COVID-19 and variants of concern.
Pharmadrug advances PD-001, its improved version of cepharanthine
